Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia: The PROMISE III Trial

NCT05313165 is registered in ClinicalTrials.gov with LimFlow, Inc. as lead sponsor.

NCT NCT05313165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05313165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia: The PROMISE III Trial
Lead sponsor
LimFlow, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
December 22, 2022
Completion date
May 1, 2027
Enrollment
100 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

chronic limb-threatening ischemia, critical limb ischemia, peripheral arterial disease